FAJARDO, Puerto Rico and ROCKAWAY, N.J., March 27 /PRNewswire/ -- Warner Chilcott Company, Inc. today announced that it has filed suit against Berlex Inc. and Schering AG in the United States District Court for the District of New Jersey alleging that Berlex and Schering are willfully infringing Warner Chilcott's U.S. Patent No. 5,552,394 in connection with the marketing and sale of Yaz(R). Warner Chilcott is seeking treble damages, costs and a permanent injunction against Berlex and Schering.
Warner Chilcott's patent, which covers Warner Chilcott's recently approved product, Loestrin(R) 24 Fe, was also licensed to Barr Pharmaceuticals, Inc. in 2004 for certain products that Barr may develop. Warner Chilcott, through its U.S. affiliate, plans to launch Loestrin(R) 24 Fe in April.
"Loestrin(R) 24 Fe embodies a novel new dosing regimen for oral contraceptives and Warner Chilcott intends to vigorously defend our rights under our patent to oral contraceptive products delivering 24 days of active therapy," said Roger Boissonneault, CEO of Warner Chilcott's parent company. "In addition to recovering damages, we will seek to have Yaz(R) removed from the market."
Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the U.S.
Read more on http://www.warnerchilcott.com.
Warner Chilcott's Forward Looking Statements:
This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward- looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. For a discussion of these risk and uncertainties, see our quarterly reports to the holders of the 8-3/4% Senior Subordinated Notes due 2015 issued by the Company's affiliate, Warner Chilcott Corporation. These documents and other information are available upon request at no cost, by sending a request by email to bkozinski@wcrx.com or by mail to 100 Enterprise Drive, Rockaway, New Jersey, 07866, Attention: Beth Kozinski.
Warner Chilcott Company, Inc.
CONTACT: Paul Herendeen, Executive Vice President and Chief FinancialOfficer of Warner Chilcott Company, Inc., +1-973-442-3200,pherendeen@wcrx.com
Web site: http://www.warnerchilcott.com/
